New Study Finds Statins May Not Extend Healthy Lifespan in Older Adults Without Cardiovascular Disease

TTHealthWatch is a weekly podcast from Texas Tech. In it, Elizabeth Tracey, director of electronic media for Johns Hopkins Medicine in Baltimore, and Rick Lange, MD, president of Texas Tech Health El Paso, look at the top medical stories of the week.

This week’s topics include a treatment for advanced breast cancer, a new target for asthma and chronic obstructive pulmonary disease (COPD), statins for older people, and improving primary care for those with chronic health conditions.

In a recent study published in the New England Journal of Medicine, researchers investigated whether statins provide benefits to older adults without existing cardiovascular disease. The trial followed nearly 10,000 participants aged 70 years who had never experienced cardiovascular events, diabetes, or dementia. Participants were randomly assigned to receive either atorvastatin (Lipitor) at 40 mg daily or a placebo over a six-year period.

While the study found that statin use was associated with reduced rates of cardiovascular death, stroke, and heart attacks—ranging from 20% to 30%—participants taking statins did not experience improvements in disability-free survival. This suggests that while statins may reduce specific cardiovascular risks in this demographic, they do not necessarily extend overall lifespan or improve quality of life in older adults without pre-existing conditions.

Dr. Rick Lange emphasized that these findings support a personalized approach to prescribing statins for older patients. “Even though you’re over 70 and have an increased risk of cardiovascular disease, these individuals often die from other causes,” he noted. He recommends shared decision-making between physicians and patients when considering statin therapy in this population.

Separately, a large international study published in The Lancet examined factors influencing the quality of primary care for patients with chronic conditions across 19 countries. Analyzing data from nearly 70,000 respondents within 1,600 primary care practices, researchers identified key elements associated with improved patient experiences:

• Long-term relationships with primary care providers (more than five years)
• Access to dedicated care coordinators
• Alignment of coordination responsibilities around established provider-patient relationships

The study concluded that continuity and coordination in primary care can be effectively scaled through initiatives such as patient registration systems, workforce development programs, and interoperable health information technology platforms.

In another significant development, researchers explored novel therapeutic approaches for advanced breast cancer. A phase III trial evaluated giredestrant, a new agent targeting estrogen receptor-positive, HER2-negative breast cancers that had progressed despite standard treatments. The study included 373 women whose cancers had developed resistance to initial therapies.

Patients were randomized to receive either standard endocrine therapy plus everolimus, or giredestrant plus everolimus. Results showed that the experimental group achieved a median progression-free survival of 10 months compared to 5.5 months in the control group, particularly among patients with specific estrogen receptor mutations present in approximately 55% of cases.

Dr. Elizabeth Tracey highlighted the importance of ongoing tumor genotyping throughout cancer progression: “As cancers evolve and acquire additional mutations, targeted therapies based on current genetic profiles can offer meaningful clinical benefits.”

Finally, early-stage research presented in Nature Medicine introduced an innovative inhaled therapy using small interfering RNA technology to target pulmonary inflammation in asthma and COPD patients. The investigational compound, ARO-RAGE, inhibits the receptor for advanced glycation end products (RAGE), which plays a central role in sustaining inflammatory responses in lung tissues.

In phase I trials involving both healthy volunteers and asthma patients, the treatment demonstrated acceptable safety profiles and minimal systemic exposure. Researchers noted that current management strategies for asthma and COPD primarily rely on bronchodilators and immunosuppressive medications like prednisone, which may be insufficient for some patients. This novel approach represents a promising addition to existing anti-inflammatory treatments.

Source link